ABSTRAm. The output of urinary IGF-I1 was measured by RIA in 12-h overnight urine samples obtained from 22 preterm and 15 full-term infants, 40 normal children, 18 children with growth hormone (GH) deficiency, and 25 patients with idiopathic short stature. GH deficiency was defined as a peak to GH provocative tests 59.9 pg/L during two provocative tests. The authenticity of urinary IGF-I1 was confirmed by size exclusion chromatography. Statistical analysis was performed by one-way analysis of variance using the Student Neuman-Keuls test to detect intergroup differences at the level of p < 0.05. The preterm and full-term infants excreted significantly higher amounts of urinary IGF-I1 (18.4 2 1.7 and 5.7 f 1.0 pmollkg, respectively) compared with normal children (2.4 f 0.25 pmol/ kg; p < 0.001). The output of urinary IGF-I1 in preterm infants was greater than that observed in full-term infants ( F = 84.7, p < 0.001). The control children excreted significantly more IGF-II(2.4 0.2 pmollkg) than children with GH deficiency (0.9 f 0.1 pmol/kg) or idiopathic short stature (1.0 f 0.1 pmol/kg; F = 13.5; p < 0.001). Analysis of urinary IGF-I1 excretion based on creatinine output yielded similar results. Data on urinary IGF-I and GH previously published were correlated and compared with the excretion pattern of urinary IGF-11. Urinary GH correlates with urinary IGF-I1 in groups 3,4, and 5 (0.58 and 0.46 per body weight and nmol of creatinine, respectively; p < 0.01), as well as in the preterm and full-term infants (0.51, p < 0.01; 0.54, p < 0.01) when the data were standardized for kg of body weight and nmol of creatinine, respectively. Children with GH deficiency excrete significantly less IGF-I1 compared with control subjects. This pattern is similar to that of urinary IGF-I. The highest urinary IGF-I1 output is observed in preterm infants, possibly reflecting a period of persistent elevation of IGF-I1 secondary to the young gestational age of these infants. (Pediatr Res 34: 435-438, 1993) Abbreviations GH, growth hormone
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The aim of this study was to quantitate and compare the urinary excretion of IGF-11 in healthy growing preterm and fullterm infants and children with normal and abnormal growth. Also, we analyzed the excretion of both urinary IGF-I and IGF-I1 to determine whether the simultaneous measurement of these peptides can better discriminate children with GH deficiency or idiopathic short stature from normal subjects. The data on urinary IGF-I have been previously published (2-4).
MATERIALS AND METHODS
We studied 22 preterm infants (43.1 f 7.2 d, group I), 17 fullterm infants (1.8 + 0.2 d, group 2), 40 normal children (9.5 + 0.6 y, group 3), 15 children with GH deficiency (1 1.2 f 0.5 y, group 4), and 24 children with idiopathic short stature (12.8 f 0.6 y, group 5) ( Table 1 ). The gestational age and corrected gestational age of the preterm infants were 30.3 + 0.8 and 36.1 f 0.5 wk, respectively. The children with GH deficiency and idiopathic short stature were followed at the endocrine clinic of the Children's Hospital of Buffalo. All were growing at a pathologic rate for age (less than 4.0 cm/y) and had a height lower than 2 SD from the mean. The height measurements were performed by trained personal using a Harpendon stadiometer (Holtein Limited). The tests used to diagnose GH deficiency were L-arginine (0.5 mg/kg) and insulin-induced (0.1 U/kg) hypoglycemia, or L-dopa administration (125 mg, <I5 kg body weight; 250 mg, 15 to 30 kg; 500 mg, >30 kg). The children diagnosed with GH deficiency had a peak GH 59.9 pg/L (5.5 + 0.6) during two of the above stimulation tests. Idiopathic short stature was diagnosed when the children had a peak GH to stimulation test r 10.0 pg/L (15.7 f 1.0). The group of normal children was composed of healthy volunteers who had height within 2 SD from the mean and were growing at a normal rate. Most of the infants and control groups in this study were composed of children included in our earlier studies (2-4). These children and their parents were all highly motivated to participate in the study and to perform the urine collection correctly. The clinical and demographic data of the population studied are presented in Table 1 . The research protocol was approved by the review board at our institution, and all parents gave written informed consent for their child's participation. None of the infants' prenatal histories were positive for maternal drug use during pregnancy or gestational diabetes. There was no clinical or laboratory evidence of intrauterine infection. All participants had normal urinalyses.
In the infants (groups 1 and 2), urine samples were collected for a 12-h period during either the day or night by means of a plastic urine bag, which was emptied periodically by the nursing staff. All diapers were weighed to validate the completeness of the collection. If a sample was contaminated by stools, the previous urine samples were discarded and the collection process was restarted. In the control group (group 3), urine samples were collected under parental supervision at home during a 12-h overnight period (2000 to 0800 h). The parents received detailed instructions. In the two groups with short stature (groups 4 and 5), the urine samples were collected in the hospital overnight before administration of the GH provocative tests.
The urine samples were kept refrigerated at 4°C throughout the collection period. Each urine sample was centrifuged to remove particulate matter and either dialyzed immediately or stored at -20°C for later dialysis. Details on the dialysis and lyophilization procedures have been previously published (2-4). The urine concentrates were extracted using a formic acidacetone extraction developed at Eli Lilly (Indianapolis, IN) by Bowsher et al. (6) . Formic acid (50 pL, 8 M) and 350 pL of acetone were added to 100 pL of sample in a polypropylene tube. After vortexing, the samples were centrifuged (3000 rpm) for 20 min at 4°C and the supernatant was aspirated. The supernatant was diluted 10-fold with assay buffer. Urinary IGF-11 was measured in duplicate by RIA using an assay developed at Lilly Research Laboratories (Indianapolis, IN) for determination of plasma IGF-11. The assay was validated for the determination of IGF-I1 urinary values. The intra-assay and interassay coefficients of variation for the RIA were 6.5 and 9.6%, respectively. The slope of the four-parameters logistic fit was 1.1 5 0.1 (mean + SD). The midrange of the assay was 1 .O to 1.4 ng/mL (0.13 to 0.19 nmol/L), with a minimum detectable concentration of 0.19 ng/mL (0.03 nmol/L). The assay uses an anti-IGF-I1 MAb from Amano Pharmaceutical (Troy, VA). Specificity data supplied by Amano Pharmaceutical indicate that bovine insulin and human epidermal growth factor do not cross-react with the antibody, whereas a 10% cross-reactivity with human IGF-I was found. The radiolabeled IGF-I1 ('*'I-IGF-11) was provided by Lilly. Recovery of added recombinant IGF-I1 (2.5 to 10.0 ng) was 82 to 93% (Table 2 ). Serial dilutions ( 1 5 to 1:40) of the urine concentrates confirmed linearity ( Table 3) .
Size-exclusion chromatography on Superose 12 was performed on extracted urine concentrates. The Superose 12 column (I x 30 cm) was equilibrated with a phosphate buffer (0.0 1 M sodium phosphate, 0.14 M NaCI, 0.01% sodium azide, 0.05% Tween 20, pH 7.2) at a flow rate of0.5 mL/min. Standard proteins were dissolved in the phosphate buffer. The samples were prepared by formic acid-acetone extraction: 200 pL of 8 M formic acid/0.5% Tween 20 were added to 400 pL of the sample, which was subsequently vortexed. After having added 1400 pL acetone, the sample was vortexed and centrifuged for 15 min at 3500 rpm: 1800 pL supernatant then were added to a second tube containing 400 mg BSA and a neutralizing amount of Tris base. The sample was dried on a speed-vac concentrator and then reconstituted in 400 pL of water before 200 pL were injected on the HPLC. Detection was performed by absorbance at 280 nm and by collecting I-min fractions at the detector outlet for IGF-I1 RIA.
Urinary creatinine was measured using the Jaffe method. The data, expressed as mean + SEM, were standardized for kg of body weight and mol of creatinine. Statistical analysis was performed by one-way analysis of variance using the Student-Neuman-Keuls test to detect intergroup differences at the level of p < 0.05.
RESULTS
The data on urinary IGF-I1 excretion in the preterm infants (group I), full-term infants (group 2), normal children (group 3). children with GH deficiency (group 4), and children with idiopathic short stature (group 5) are shown in Table 4 Figure 1 shows the chromatographic profile of an extracted urine sample applied to Superose 12 column. IGF-I1 immunoreactivity peaks at the position were authentic IGF-I1 elutes.
Analysis of urinary IGF-11 excretion based on creatinine output nmol/g of creatinine) yielded results comparable to those based on body weight: Preterm and full-term infants secreted significantly higher amounts of both peptides (437.5 + 58.1 and 128.4 + 32.0 nmol/mol creatinine, respectively) compared with normal children (33.2 + 3.8 nmol/mol creatinine: F = 63.3; p < 0.001). Also, a significant difference was observed between the latter group and children with GH deficiency or idiopathic short stature (12.9 f 2.0 and 15.2 + 2.0 nmol/mol creatinine, respectively; F = 9.5; p < 0.001; Table 2 ). The data on the urinary output of GH and IGF-I have been previously published (2-4). A significant correlation was observed between the urinary output of IGF-I and IGF-I1 in children with normal and short stature (groups 3, 4, and 5) when data were standardized by either body weight or mol of creatinine ( r = 0.60 and 0.38, respectively; p < 0.001). In our previous work, we reported a positive correlation between IGF-I and GH urinary output (2) . The latter correlates also with IGF-I1 in groups 3, 4, and 5 (r = 0.58 and 0.46 per body weight and g of creatinine, respectively). Also, in the preterm and full-term infants, a positive correlation was found between urinary GH and IGF-I1 (r = 0.51 and 0.54, p c 0.01) when the data were standardized for kg of body weight URINARY IGF-11 OUTPUT IN INFANTS AND CHILDREN 437 * Conversion factor for IGF-11 to nmol/L is 0.1333. Fig. I . Chromatographic profile of extracted urine sample. IU conversion factor from ng/mL to nmol/L is 0.1333. and creatinine (nmol), respectively. In the preterm group, an inverse correlation was found between corrected gestational age and urinary IGF-I1 output (-0.70, p < 0.001) when data were standardized by kg of body weight.
DISCUSSION
Our data show that the urinary output of IGF-I1 is significantly greater in infants compared with children, similar to the relationship previously observed for the urinary excretion of IGF-I in the content of binding protein is lower in urine than in plasma (16. 17) .
We previously have addressed the potential problem of renal immaturity causing a higher urinary output of IGF (3). As previously observed in the urinary IGF-I excretion, no correlation was found between pz microglobulin and urinary IGF-I1 output. The data on pz microglobulin have been previously published (3).
Children with GH deficiency or idiopathic short stature exhibit a pattern of urinary IGF-I1 excretion similar to that previously reported for IGF-I and GH output, i.e. the mean urinary IGF-I1 output is significantly lower in short children compared with control subjects (4). However, overlap among the groups suggests that the isolated determination of urinary IGF-I1 would not differentiate children with GH deficiency or idiopathic short stature from normal subjects. Also, the simultaneous measurement of both peptides does not increase substantially the specificity of the screening test.
In conclusion, the overlap of urinary IGF-I and IGF-I1 values, more marked between controls and children with idiopathic short stature, strongly limits their usefulness as a screening and diagnostic tool. Because children with idiopathic short stature have a normal response to GH stimulation tests, a decision about GH therapy in this population must be based on their height and growth rate.
